Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.

@article{Henry2001AntiviralAA,
  title={Antiviral activity and ocular kinetics of antisense oligonucleotides designed to inhibit CMV replication.},
  author={Scott P. Henry and Richard C Miner and William Lawrence Drew and Jon Fitchett and Cathie York-DeFalco and Laurence M. Rapp and Arthur A. Levin},
  journal={Investigative ophthalmology & visual science},
  year={2001},
  volume={42 11},
  pages={2646-51}
}
PURPOSE To compare the antiviral activity and ocular distribution of first- and second-generation antisense oligonucleotides intended for the treatment of cytomegalovirus (CMV) retinitis. METHODS The antiviral activity of ISIS 13312 and ISIS 2922 (Isis Pharmaceuticals, Inc., Carlsbad, CA) against 10 clinical CMV isolates was compared with a plaque-reduction assay. The ocular pharmacokinetics were compared after intravitreal injection in rabbits (36-90 microg) and monkeys (125-500 microg… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 10 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 24 references

Fomivirsen

  • CM Perry, JA BarmanBalfour
  • Drugs .
  • 1999

Treatment of retinitis induced by cytomegalovirus using intravitreal formivirsen (ISIS 2922)

  • ST Crooke
  • Clinical Trials of Genetic Therapy with Antisense…
  • 1998
1 Excerpt

Antisense oligonucleotide (fomivirsen sodium) treatment of CMV retinitis unresponsive to other antiviral therapies [ARVO Abstract

  • R Lieberman, A Antoszyk, D Boyer
  • Invest Ophthalmol Vis Sci
  • 1997
1 Excerpt

Similar Papers

Loading similar papers…